Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2009 1
2010 3
2011 4
2012 1
2014 1
2015 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Chromosomal instability determines taxane response.
Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J. Swanton C, et al. Proc Natl Acad Sci U S A. 2009 May 26;106(21):8671-6. doi: 10.1073/pnas.0811835106. Epub 2009 May 19. Proc Natl Acad Sci U S A. 2009. PMID: 19458043 Free PMC article.
CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.
Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA, Swanton C. Lee AJ, et al. J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19. J Pathol. 2012. PMID: 21953249
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.
Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Juul N, et al. Lancet Oncol. 2010 Apr;11(4):358-65. doi: 10.1016/S1470-2045(10)70018-8. Epub 2010 Feb 26. Lancet Oncol. 2010. PMID: 20189874 Free article.
12 results